Emergence of SARS-CoV-2 Delta Variant and Effect of Nonpharmaceutical Interventions, British Columbia, Canada.
B.1.617.2 SARS-CoV-2 variant
British Columbia
COVID-19
Canada
SARS-CoV-2
SARS-CoV-2 Delta variant
communicable disease control
disease transmission
infectious
physical distancing
public health
respiratory infections
severe acute respiratory syndrome coronavirus 2
vaccination
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
22
9
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
In British Columbia, Canada, initial growth of the SARS-CoV-2 Delta variant was slower than that reported in other jurisdictions. Delta became the dominant variant (>50% prevalence) within ≈7-13 weeks of first detection in regions within the United Kingdom and United States. In British Columbia, it remained at <10% of weekly incident COVID-19 cases for 13 weeks after first detection on March 21, 2021, eventually reaching dominance after 17 weeks. We describe the growth of Delta variant cases in British Columbia during March 1-June 30, 2021, and apply retrospective counterfactual modeling to examine factors for the initially low COVID-19 case rate after Delta introduction, such as vaccination coverage and nonpharmaceutical interventions. Growth of COVID-19 cases in the first 3 months after Delta emergence was likely limited in British Columbia because additional nonpharmaceutical interventions were implemented to reduce levels of contact at the end of March 2021, soon after variant emergence.
Identifiants
pubmed: 37640374
doi: 10.3201/eid2910.230055
pmc: PMC10521616
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1999-2007Références
PLoS One. 2021 Jul 21;16(7):e0253510
pubmed: 34288910
Nature. 2022 Oct;610(7930):154-160
pubmed: 35952712
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Cell Rep Med. 2022 Mar 11;3(4):100583
pubmed: 35480627
PLoS Comput Biol. 2020 Dec 3;16(12):e1008274
pubmed: 33270633
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Emerg Infect Dis. 2022 Mar;28(3):650-659
pubmed: 35133957
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Nature. 2021 Jul;595(7869):713-717
pubmed: 34192736
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7504-7509
pubmed: 32170017